2.8187

4.08% -0.1213

Aptevo Therapeutics Inc (APVO)

Overview News Price History Financials Discussions Forecast Stock Split

Aptevo Therapeutics Inc stock is traded at $2.8187, with a volume of 50,816. It is down -4.08% in the last 24 hours and down -40.51% over the past month. Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, CD3xCD123, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

Previous Close:

$2.94

Open:

$2.99

24h Volume:

50,816

Relative Volume:

1.05

Market Cap:

$4.31M

Revenue:

$12.99M

Net Income/Loss:

$-27.83M

P/E Ratio:

-0.0138

EPS:

-203.7366

Net Cash Flow:

$-26.98M

1W Performance:

-29.85%

1M Performance:

-40.51%

6M Performance:

-60.56%

1Y Performance:

-92.17%

1-Day Range:

$2.8099

$2.99

1-Week Range:

$2.8099

$4.155

52-Week Range:

$2.8099

$48.78

Aptevo Therapeutics Inc Stock (APVO) Company Profile

Name

Aptevo Therapeutics Inc

Sector

Healthcare (1089)

Industry

Biotechnology (604)

Phone

206-838-0500

Address

2401 4TH AVE., SEATTLE, WA

Employee

Twitter

@aptevo

Next Earnings Date

2026-08-17

Latest SEC Filings

APVO's Discussions on Twitter

Compare APVO vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
APVO Aptevo Therapeutics Inc	2.84	4.46M	12.99M	-27.83M	-26.98M	-203.74
VRTX Vertex Pharmaceuticals Inc	515.33	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	807.80	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	992.01	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	212.13	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.05	39.31B	5.76B	514.49M	1.10B	4.4813

Aptevo Therapeutics Inc Stock (APVO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-05-18	Initiated	Ladenburg Thalmann	Buy
Oct-05-17	Resumed	Piper Jaffray	Overweight

Aptevo Therapeutics Inc Stock (APVO) Latest News

07:27 AM

Weekly Recap: APVO H1 losses and Aug 13 financing via warrants, PIPE - TradingView

07:27 AM

Aug 14, 2026

Aptevo Therapeutics (APVO): CVI and Heights disclose 6.3% warrant-based stake - Stock Titan

Aug 14, 2026

Aptevo Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 14, 2026

Form 8K Aptevo Therapeutics Inc For: 14 August By Investing.com - Investing.com Nigeria

Aug 14, 2026

Aptevo Therapeutics Inc. 6M 2026: Net loss $(13.15M), Diluted EPS $(11.19) — 10-Q Summary - TradingView

Aug 14, 2026

Aptevo APVO Reports Q2 2026 Update With $9.8 Million Cash - Quiver Quantitative

Aug 14, 2026

Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results - ACCESS Newswire

Aug 14, 2026

Aptevo's Mipletamig Shows 81% Remission in 31 Leukemia Patients - Stock Titan

Aug 14, 2026

Aug 13, 2026

Aptevo Therapeutics Raises Capital Through Warrant-Induced Financing - TipRanks

Aug 13, 2026

Aptevo raises $4.5 million through warrant and equity financing By Investing.com - Investing.com Nigeria

Aug 13, 2026

Aptevo Raises $4.5 Million Via Warrant Exercises and PIPE; Issues 5.6M Warrants at $4.03 - TradingView

Aug 13, 2026

Aptevo raises $4.5 million through warrant and equity financing - Investing.com

Aug 13, 2026

Aptevo Therapeutics Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross Proceeds - ACCESS Newswire

Aug 13, 2026

New Aptevo warrants for 4.3M shares await stockholder approval - Stock Titan

Aug 13, 2026

Aug 12, 2026